International Distribution of Astute
Medical’s Biomarker Technologies
Astute Medical identifies and validates novel biomarkers for acute conditions and disease states. We use the discovery of new biomarkers to develop technologies that can assist the clinician in earlier, more reliable patient assessment for risk of acute kidney injury (AKI) and other life-threatening conditions.
Our new products, the NephroCheck Test® and theAstute140® Meter, used together provide early AKI risk assessment—with results in approximately 20 minutes. Astute Medical is partnering with respected distributors to make these viable clinical tools available in many countries: